Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Niraparib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05961124
What this trial is testing

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Who this might be right for
Ovarian CancerStage III Ovarian CancerStage IV Ovarian Cancer+1 more
Sunnybrook Health Sciences Centre 40
Early research (Phase 1)Study completedNCT03497429
What this trial is testing

Niraparib as Single Agent in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Takeda 9
Early research (Phase 1)Ended earlyNCT01227941
What this trial is testing

MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

Who this might be right for
Ovarian Cancer
Tesaro, Inc. 6
Early research (Phase 1)Study completedNCT00749502
What this trial is testing

MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Who this might be right for
Solid TumorsChronic Lymphocytic LeukemiaT-cell-prolymphocytic Leukemia
Tesaro, Inc. 113
Large-scale testing (Phase 3)Active Not RecruitingNCT04915755
What this trial is testing

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 40
Testing effectiveness (Phase 2)Ended earlyNCT04826198
What this trial is testing

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Who this might be right for
Ovarian Cancer
Gustave Roussy, Cancer Campus, Grand Paris 13
Not applicableStudy completedNCT06086665
What this trial is testing

The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
Asan Medical Center 850
Testing effectiveness (Phase 2)Ended earlyNCT06964165
What this trial is testing

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 36
Early research (Phase 1)Study completedNCT02044120
What this trial is testing

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Who this might be right for
Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration 34
Large-scale testing (Phase 3)Active Not RecruitingNCT03602859
What this trial is testing

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal Carcinoma
Tesaro, Inc. 1,400
Testing effectiveness (Phase 2)Looking for participantsNCT06747845
What this trial is testing

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Who this might be right for
Pancreatic Adenocarcinoma Metastatic
Abramson Cancer Center at Penn Medicine 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT03830918
What this trial is testing

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Who this might be right for
Advanced Malignant Solid NeoplasmExtensive Stage Lung Small Cell CarcinomaStage III Lung Cancer AJCC v8+6 more
Jonsson Comprehensive Cancer Center 59
Testing effectiveness (Phase 2)Study completedNCT05130515
What this trial is testing

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.

Who this might be right for
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 6
Testing effectiveness (Phase 2)Study completedNCT03326193
What this trial is testing

Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 105
Early research (Phase 1)Ended earlyNCT04178460
What this trial is testing

Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Who this might be right for
Gastric CancerTriple Negative Breast CancerBiliary Tract Carcinoma+1 more
Zai Lab (Shanghai) Co., Ltd. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03983993
What this trial is testing

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

Who this might be right for
Advanced Microsatellite Stable Colorectal CarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaMicrosatellite Stable+3 more
Emory University 26
Early research (Phase 1)UnknownNCT04764084
What this trial is testing

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Who this might be right for
HER2-negative Breast CancerGastric AdenocarcinomaCholangiocarcinoma+1 more
Peking University Cancer Hospital & Institute 52
Not applicableStudy completedNCT05021562
What this trial is testing

Niraparib in Patients With Ovarian Cancer in Clinical Practice

Who this might be right for
Ovarian Cancer
Takeda 354
Testing effectiveness (Phase 2)Active Not RecruitingNCT04221503
What this trial is testing

Niraparib/TTFields in GBM

Who this might be right for
GlioblastomaRecurrent GlioblastomaGBM
Abramson Cancer Center at Penn Medicine 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03748641
What this trial is testing

Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Who this might be right for
Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC 765
Next Page